# Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD

> **NCT04468360** · PHASE2 · RECRUITING · sponsor: **Boston University** · enrollment: 256 (estimated)

## Conditions studied

- Post Traumatic Stress Disorder

## Interventions

- **BEHAVIORAL:** 3-day differential fear conditioning, extinction, and extinction retention testing paradigm
- **DRUG:** Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis
- **OTHER:** Matching IV Placebo

## Key facts

- **NCT ID:** NCT04468360
- **Lead sponsor:** Boston University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-04
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04468360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04468360, "Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04468360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*